Prospective Evaluation of Breast-Conserving Surgery Alone in Low Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined with Clinico-Pathological Features

分子表达分析结合临床病理特征对单纯保乳手术治疗低危导管原位癌的前瞻性评估

• 批准号: 420916
• 负责人: Rakovitch Eileen
• 金额: $ 90万
• 依托单位: Ontario Clinical Oncology Group
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-03-01 至 2026-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=420916&lang=en
• 关键词: Breast Cancer; Dcis; Low Risk; Molecular Assay; Radiotherapy

Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer that represents over 25% of all new breast cancers in North America. Treatment is recommended given the potential of DCIS to progress to invasive cancer. Most women are treated with breast-co

导管原位癌（DCIS）是一种非侵袭性乳腺癌，占北美所有新发乳腺癌的25%以上。考虑到DCIS进展为浸润性癌症的可能性，建议进行治疗。大多数女性都接受了乳腺癌治疗。